The study evaluated the efficacy and safety of ABP 215 compared with Avastin (bevacizumab) in adult patients with advanced non-squamous non-small cell lung cancer (NSCLC).
"Amgen is committed to bringing high-quality, reliably supplied medicines to patients, and we're excited to leverage our development and manufacturing capabilities in oncology for our biosimilars," Dr. Sean Harper, Amgen's executive vice president of research and development, said. "The positive Phase 3 results from the ABP 215 study showed clinical equivalence in efficacy, and comparable safety and immunogenicity, to bevacizumab."
NSCLC is the No. 1 cause of cancer death in both men and women in the U.S. and Europe.
"The positive Phase 3 clinical results of ABP 215 mark an important step forward in the development of biosimilar treatment options for patients with advanced non-small cell lung cancer," David Nicholson, executive vice president and president of global research and development of Allergan, said.
For more information, log on to www.amgen.com or www.allergan.com.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics
Allergan is a global, technology-driven multi-specialty health care company pursuing therapeutic advances to help patients live life to their fullest potential.